维生素B6可预测不同地域原发性硬化性胆管炎患者的不良结局
该研究在挪威、美国和德国三个原发性硬化性胆管炎(PSC)队列中验证血清活性维生素B6(PLP)对无肝移植生存和肝功能失代偿的预测价值。结果显示维生素B6缺乏在斯堪的纳维亚以外也常见,低PLP与更短的无肝移植生存及更高的肝功能失代偿发生率相关,且能提升现有预测模型的判别能力。
要点
- 维生素B6缺乏(PLP<20 nmol/L)在PSC患者中常见,且与不良结局相关。
- 低PLP与更短的无肝移植生存相关,并在现有预测模型之上提供增量预测价值。
- 低PLP与肝功能失代偿发生率升高相关,尤其在失代偿更常见的美国队列中明显。
核心结论
- 维生素B6缺乏在斯堪的纳维亚以外的PSC人群中常见,且在不同地域PSC人群中一致与不良结局相关。
研究设计与样本
- 回顾性队列研究,纳入挪威(n=315)、美国(n=756)和德国(n=149)的PSC患者,采用液相色谱-串联质谱法检测血清活性维生素B6(PLP)。
- 采用Cox比例风险模型和Fine-Gray竞争风险模型分别评估PLP对无肝移植生存和肝功能失代偿累积发生率的预测能力。
主要发现
- 在未移植的PSC患者中,维生素B6缺乏(PLP<20 nmol/L)的患病率在挪威队列为50%,在美国队列为25%。
- 有既往肝功能失代偿者的维生素B6缺乏患病率更高。
- 美国队列的肝功能失代偿累积发生率更高,而挪威队列更多因肝功能失代偿以外的指征接受肝移植。
- 尽管临床实践存在差异,低PLP一致与更短的无肝移植生存相关,并在现有预测模型之上对肝移植或PSC死亡提供增量预测价值。
- 低PLP与更高的肝功能失代偿发生率相关,主要在美国队列中明显;两种结局的风险在缺乏和边缘缺乏范围内急剧升高,在PLP充足水平趋于平稳。
临床怎么用
- 可考虑检测PSC患者的血清PLP以识别维生素B6缺乏或边缘缺乏者,并关注其无肝移植生存和肝功能失代偿风险。
- 对于PLP处于边缘至明确缺乏范围的PSC患者,应关注恢复维生素B6充足状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) has a variable disease course, complicating patient counseling and the timing of liver transplantation. Vitamin B6 deficiency predicts reduced liver transplantation-free survival in Scandinavian PSC cohorts. Here, we aimed to validate this observation in US and German PSC cohorts and to expand our analyses to include hepatic decompensation as a clinical outcome. METHODS: Serum active vitamin B6 (pyridoxal 5'-phosphate [PLP]) was analyzed using liquid chromatography-tandem mass spectrometry in retrospective cohorts of people with PSC from Norway (n = 315), the USA (n = 756), and Germany (n = 149). Cox proportional hazards and Fine and Gray competing risk models were fitted to estimate the ability of PLP to predict liver transplantation-free survival and the cumulative incidence of hepatic decompensation, respectively. RESULTS: The prevalence of vitamin B6 deficiency (PLP <20 nmol/L) in pre-transplant PSC was 50% in the Norway cohort and 25% in the USA cohort. The prevalence was higher among those with previous hepatic decompensation. The cumulative incidence of hepatic decompensation was higher in the USA cohort, while individuals in the Norway cohort were more commonly transplanted for indications other than hepatic decompensation. Despite differences in clinical practice, low PLP was consistently associated with shorter liver transplantation-free survival, and PLP added predictive value for liver transplantation or death from PSC over and above contemporary prediction models. Low PLP was also associated with a higher incidence of hepatic decompensation, which was mainly evident in the USA cohort, where decompensation was more common. The risk of both outcomes increased sharply within the deficient and marginal ranges and plateaued at sufficient PLP levels. CONCLUSIONS: Vitamin B6 deficiency is common in PSC outside Scandinavia and is consistently associated with poor outcomes across geographically distinct PSC populations. IMPACT AND IMPLICATIONS: We previously showed that vitamin B6 deficiency is prevalent and associated with reduced liver transplantation-free survival in Scandinavian PSC cohorts. The current work shows that these observations generalize to a US population and that low vitamin B6 is also associated with the development of hepatic decompensation. Our results indicate that vitamin B6 provides incremental value for predicting outcomes in PSC across geographically distinct populations and that efforts to restore B6 sufficiency should be focused on the many individuals who present with vitamin B6 levels within the marginal-to-definitive deficiency range.
引用
- Braadland PR, Ali AH, Puchas P, et al. Vitamin B6 predicts poor outcomes in geographically distinct populations with primary sclerosing cholangitis. J Hepatol. 2026. PMID: 42002000. doi:10.1016/j.jhep.2026.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。